Rhumbline Advisers Amgen Inc Transaction History

Rhumbline Advisers

$103 Billion
Q1 2024

A detailed history of Rhumbline Advisers transactions in Amgen Inc stock. As of the latest transaction made, Rhumbline Advisers holds 1,061,924 shares of AMGN stock, worth $330 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares

1,061,924

Previous 1,064,221 0.22%

Holding current value

$330 Million

Previous $307 Million 1.5%

% of portfolio

0.29%

Previous 0.32%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$268.87 - $324.56 $617,594 - $745,514	-2,297 Reduced 0.22%	1,061,924 $302 Million
Q4 2023 Feb 08, 2024	BUY	$255.7 - $288.46 $759,429 - $856,726	2,970 Added 0.28%	1,064,221 $307 Million
Q3 2023 Nov 09, 2023	BUY	$218.65 - $271.46 $2.4 Million - $2.98 Million	10,962 Added 1.04%	1,061,251 $285 Million
Q2 2023 Aug 08, 2023	BUY	$214.27 - $253.37 $2.58 Million - $3.05 Million	12,035 Added 1.16%	1,050,289 $233 Million
Q1 2023 May 11, 2023	BUY	$225.79 - $275.2 $8.27 Million - $10.1 Million	36,641 Added 3.66%	1,038,254 $251 Million

Q4 2022 Feb 14, 2023	BUY	$229.03 - $291.01 $6.99 Million - $8.88 Million	30,522 Added 3.14%	1,001,613 $263 Million
Q3 2022 Nov 10, 2022	BUY	$224.46 - $253.15 $10.3 Million - $11.6 Million	46,014 Added 4.97%	971,091 $219 Million
Q2 2022 Aug 11, 2022	SELL	$230.71 - $256.74 $4.89 Million - $5.44 Million	-21,198 Reduced 2.24%	925,077 $225 Million
Q1 2022 May 12, 2022	BUY	$219.27 - $242.57 $130,246 - $144,086	594 Added 0.06%	946,275 $229 Million
Q4 2021 Feb 10, 2022	BUY	$198.88 - $227.6 $2.66 Million - $3.05 Million	13,379 Added 1.44%	945,681 $213 Million
Q3 2021 Nov 12, 2021	SELL	$212.27 - $248.7 $11.5 Million - $13.4 Million	-54,029 Reduced 5.48%	932,302 $198 Million
Q2 2021 Aug 05, 2021	SELL	$233.58 - $259.14 $12.9 Million - $14.3 Million	-55,094 Reduced 5.29%	986,331 $240 Million
Q1 2021 May 06, 2021	SELL	$221.91 - $258.6 $21.8 Million - $25.4 Million	-98,088 Reduced 8.61%	1,041,425 $259 Million
Q4 2020 Feb 10, 2021	SELL	$216.38 - $257.67 $4.75 Million - $5.66 Million	-21,963 Reduced 1.89%	1,139,513 $262 Million
Q3 2020 Nov 12, 2020	BUY	$234.65 - $260.95 $10.4 Million - $11.5 Million	44,191 Added 3.96%	1,161,476 $295 Million
Q2 2020 Aug 13, 2020	BUY	$197.81 - $242.74 $15.9 Million - $19.5 Million	80,302 Added 7.74%	1,117,285 $264 Million
Q1 2020 May 06, 2020	SELL	$182.24 - $241.7 $987,011 - $1.31 Million	-5,416 Reduced 0.52%	1,036,983 $210 Million
Q4 2019 Feb 05, 2020	SELL	$189.21 - $243.2 $1.49 Million - $1.91 Million	-7,870 Reduced 0.75%	1,042,399 $251 Million
Q3 2019 Oct 23, 2019	BUY	$174.11 - $208.62 $1.83 Million - $2.2 Million	10,536 Added 1.01%	1,050,269 $203 Million
Q2 2019 Aug 14, 2019	SELL	$166.7 - $195.41 $5.43 Million - $6.36 Million	-32,569 Reduced 3.04%	1,039,733 $192 Million
Q1 2019 May 01, 2019	BUY	$180.87 - $203.88 $6.1 Million - $6.87 Million	33,709 Added 3.25%	1,072,302 $204 Million
Q4 2018 Jan 31, 2019	SELL	$178.4 - $208.25 $23.1 Million - $27 Million	-129,554 Reduced 11.09%	1,038,593 $202 Million
Q3 2018 Nov 07, 2018	SELL	$185.29 - $208.89 $15.6 Million - $17.6 Million	-84,029 Reduced 6.71%	1,168,147 $242 Million
Q2 2018 Aug 06, 2018	SELL	$166.05 - $186.51 $11.7 Million - $13.1 Million	-70,381 Reduced 5.32%	1,252,176 $231 Million
Q1 2018 May 02, 2018	SELL	$169.43 - $198.0 $14.9 Million - $17.4 Million	-87,844 Reduced 6.23%	1,322,557 $225 Million
Q4 2017 Feb 09, 2018	BUY	$168.79 - $188.59 $7.79 Million - $8.71 Million	46,167 Added 3.38%	1,410,401 $245 Million
Q3 2017 Nov 06, 2017	BUY	$167.29 - $191.0 $228 Million - $261 Million	1,364,234	1,364,234 $254 Million

Others Institutions Holding AMGN

# of Institutions

2,932

Shares Held

401M

Call Options Held

6.59M

Put Options Held

6.6M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $166B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Amgen Inc Transaction History